Sandhya Girish - Concepedia

Author

Sandhya Girish

Also Known As

GIRISH S M, Girish S, S Girish, S R Girish, S. Girish, Sandhya GIRISH, Sandhya Girish, Sandhya R. Girish, Sandhya Ramanathan Girish

140

Publications

5.4K

Citations

H-Index

Concepts

All Affiliations

Roche (Switzerland)Dana-Farber Cancer Institute Certara (United States)Roche (France)Gene Therapy Laboratory

About

Sandhya Girish is an author at Roche (Switzerland) specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	27	1.1K
2	Biochemistry	2	2	87
3	Health Sciences	1	1	16
4	Natural Sciences	1	1	76
5	Biostatistics	1	1	26

Sandhya Girish

Publications

4.3K

Citations

H-Index

Page 1

	Year	Citations
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy Howard A. Burris, Hope S. Rugo, Svetislava J. Vukelja, Journal of Clinical Oncology	2010	758
Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer Ian E. Krop, Muralidhar Beeram, Shanu Modi, Journal of Clinical Oncology	2010	590
A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine Ian E. Krop, Patricia LoRusso, Kathy D. Miller, Journal of Clinical Oncology	2012	361
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer Sandhya Girish, Manish Gupta, Bei Wang, Cancer Chemotherapy and Pharmacology	2012	261
Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1) Hirdesh Uppal, Estelle Doudement, Kaushiki Mahapatra, Clinical Cancer Research	2014	199
Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability Kirsten Achilles Poon, Kelly M. Flagella, Joseph C. Beyer, Toxicology and Applied Pharmacology Breast OncologyImmunologyCytotoxic ComponentImmunotherapeuticsUnconjugated Dm1	2013	189
Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism Ben‐Quan Shen, Daniela Bumbaca, Ola M. Saad, Current Drug Metabolism OncologyTrastuzumab EmtansineClinical CatabolismOncogenic AgentCatabolic Fate	2012	135
A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer Muralidhar Beeram, Ian E. Krop, Howard A. Burris, Cancer	2012	102
A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer Brendan C. Bender, Franziska Schaedeli‐Stark, R Koch, Cancer Chemotherapy and Pharmacology Platelet CountsThrombosisThrombopoiesisPopulation Pharmacokinetic/pharmacodynamic ModelOncology	2012	87
Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting Kari M. Morrissey, Mathilde Marchand, Hina Patel, Cancer Chemotherapy and Pharmacology	2019	86

Page 1